DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vepesid (Etoposide) - Summary

 
 



WARNINGS

VePesid (etoposide) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe myelosuppression with resulting infection or bleeding may occur.

 

VEPESID SUMMARY

VePesid®
(etoposide)
Capsules

VePesid® (etoposide) (also commonly known as VP-16) is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. It is 4'-demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside]. It is very soluble in methanol and chloroform, slightly soluble in ethanol, and sparingly soluble in water and ether. It is made more miscible with water by means of organic solvents.

VePesid (etoposide) is indicated in the management of the following neoplasms:

Refractory Testicular Tumors— VePesid For Injection in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy.

Adequate data on the use of VePesid Capsules in the treatment of testicular cancer are not available.

Small Cell Lung Cancer— VePesid For Injection and/or Capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.


See all Vepesid indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Vepesid (Etoposide)

Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience. [2011.08.27]
In 1991, a prospective phase II trial was initiated to evaluate the efficacy of treatment for adults with medulloblastoma (MB). After surgery, patients were staged with a neuroradiologic examination of the brain and neuroaxis and by cerebrospinal fluid cytology.To know whether adding chemotherapy to craniospinal radiation in adult therapy increases relapse-free and overall survival, we must await the results of a larger randomized controlled clinical trial.

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). [2011.05]
CONCLUSION: This study could not demonstrate that high-dose chemotherapy given as part of first-line therapy improves outcome in patients with poor-prognosis GCC.

Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. [2011.03]
PURPOSE: A randomized clinical trial examined whether dexamethasone administration prior to ondansetron followed by etoposide and carboplatin infusions, and single-nucleotide polymorphisms (SNPs) of CYP3A4, CYP3A5 and MDR1 genes could modify etoposide pharmacokinetics in pediatric patients... CONCLUSION: Pharmacokinetics of etoposide was influenced by BW on an allometric basis in this pediatric population. Dexamethasone did not influence etoposide pharmacokinetics during these 3-5 days courses. These results should allow a better individualization of etoposide dosing in children.

Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. [2011.01]
Darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), is used in cancer patients as a supportive care for anemia. For small-cell lung cancer (SCLC), several studies have shown that the administration of ESAs does not affect survival but decreases the need for blood transfusions and improves the quality of life (QOL) of patients receiving chemotherapy...

Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. [2010.12.01]
CONCLUSIONS: The overall rate of Grade 2 to 5 RP was 7% in patients treated with chemoradiotherapy. In this analysis, predictive factors for RP were MLD > 18 Gy and treatment with CD. Copyright (c) 2010 Elsevier Inc. All rights reserved.

more studies >>

Clinical Trials Related to Vepesid (Etoposide)

Alemtuzumab in Combination With Etoposide and Dexamethasone [Not yet recruiting]
The goal of this clinical research study is to learn the if the drug combination of alemtuzumab, etoposide and dexamethasone can help to control HLH. The safety of the drug combination will also be studied.

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas [Completed]
Primary Objective: To determine maximum tolerated dose & dose limiting toxicity of vandetanib when combined with standard dosing of etoposide among patients with recurrent malignant glioma who are on & not on enzyme-inducing anti-epileptic drugs (EIAEDs) Secondary Objectives: To assess safety & tolerability of vandetanib + etoposide in this population; To evaluate pharmacokinetics of vandetanib among malignant glioma patients on & not on EIAEDs when combined with etoposide. Exploratory Objective: To evaluate for evidence of anti-tumor activity of study regimen among recurrent malignant glioma patients including radiographic response rate, 6-month progression free survival (PFS) rate & median PFS.

Ph II Bevacizumab + Etoposide for Pts w Recurrent MG [Completed]
Primary Objective to estimate 6-month progression free survival probability of patients with recurrent malignant glioma treated with Etoposide + Bevacizumab. Secondary Objectives To evaluate safety & tolerability of Etoposide + Bevacizumab among patients with recurrent malignant glioma (RMG). To evaluate radiographic response, progression free survival & overall survival of patients with recurrent malignant glioma treated with Etoposide + Bevacizumab.

Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan [Completed]
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate safety & tolerability of bev + either daily temozolomide/etoposide among pts w recurrent GBM who have progressed on bev + irinotecan To evaluate radiographic response, progression free survival & overall survival of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases [Completed]
Primary Objective:

- Determine the interindividual range and median of individual maximum tolerated doses of

valproic acid administered as one time evening dose in conjunction with a dose oral etoposide (50 mg/m2/day for children, but only 25mg/m2/day for adults to start) for four different age groups. Secondary Objectives:

- Determine the qualitative and quantitative toxicity and reversibility of toxicity of

valproic acid in conjunction with oral etoposide,

- To investigate the clinical pharmacokinetics of valproic acid when given in conjunction

with oral etoposide,

- To describe quality of life of patients with relapsed, or progressive central and

peripheral nervous system tumors when treated with oral valproic acid and etoposide,

- To observe and describe the response pattern of progressive central nervous system

tumors treated with oral valproic acid and etoposide,

- To observe and describe event free survival time and overall survival time of patients

with relapsed, or progressive central nervous system tumors when treated with oral valproic acid and etoposide,

- To determine if histone deacetylase activity and topoisomerase expression in

lymphocytes of patients is related to valproic acid levels, and

- To determine, if the individual maximal tolerated dose (iMTD) depends on the initial

performance status of the patient in the beginning of the treatment.

more trials >>

Reports of Suspected Vepesid (Etoposide) Side Effects

Neutropenia (9)Leukopenia (9)Thrombocytopenia (7)Febrile Neutropenia (5)Pyrexia (4)Subdural Haematoma (4)White Blood Cell Count Decreased (4)Vomiting (4)Alopecia (4)Myelodysplastic Syndrome (3)more >>


Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015